Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 29Terminated 5Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 21INDUSTRY 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Glioblastoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT01875653 2019-05-10

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Lisata Therapeutics, Inc.

Phase 3 Terminated
4 enrolled
Dermatologic

Melanoma

NCT01403285 2014-05-19

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Immatics Biotechnologies GmbH

Phase 1 Terminated
6 enrolled
CNS

Glioblastoma

NCT00969722 2013-03-08

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

United Therapeutics

Phase 2 Terminated
1 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡